Background: Breast cancer is a common malignancy in women. DCTPP1 is a potential target for the development of antitumor drugs, and plays an important role in the process of DNA replication. Aims: To investigate the biological role of DCTPP1 gene, as well as its expression in breast cancer and its relation to patient prognosis. Materials and Methods: Breast cancer data was derived from the TCGA database. Using the UALCAN database, the expression level of DCTPP1 mRNA in breast cancer tissues was investigated. The expression of DCTPP1 in various pathological types of breast cancer was studied using the Human Protein Atlas. UALCAN was also used to investigate the relationship between DCTPP1 gene expression and breast cancer patient prognosis. Bioinformatics studied the proteins related to DCTPP1 expression and their roles in the GeneMANIA and WebGestalt databases. Results: DCTPP1 mRNA was significantly expressed in breast cancer compared to normal breast tissue (P<0.001). DCTPP1 was shown to be highly expressed in breast cancer tissues from different pathological types and stages (P<0.001). The DCTPP1 protein was expressed at a higher frequency in breast cancer than in normal breast tissue. When compared to patients with low DCTPP1 expression, patients with high DCTPP1 expression had a considerably shorter overall survival time. The 20 proteins related to DCTPP1 expression were mostly located in the nucleus and membrane, and were involved in biological regulation, stimulus response, metabolic process, and other processes, according to gene ontology analysis. It plays an important role in protein binding, ion binding, and nucleic acid binding. Conclusion: DCTPP1 is highly expressed in breast cancer, and is associated to a poor prognosis for patients with breast cancer. DCTPP1 may be a potential therapy and intervention target for breast cancer.

Lung cancer is the leading cause of cancer death globally. Non-small cell lung cancer (NSCLC) constitutes more than 80% of all lung cancers, and patients with distant metastasis have much higher mortality. The survival times of NSCLC patients with metastasis have been reported in early studies, however, it remains unclear whether there are variations or patterns in survival times of patients with different metastases. Therefore, we assessed risk factors for distant metastases and the effects of different organ metastasis on overall survival (OS) in patients with NSCLC. Methods: demographics and clinical data of NSCLC patients with and without distant metastasis were collected from the Surveillance, Epidemiology, and End Result (SEER) database between 2010 and 2016. We investigated risk factors for distant metastasis patients and compared the difference in OS of NSCLC patients with different metastatic sites. Results: a total of 3849 patients diagnosed with NSCLC were screened from the SEER database with 41% (1577) of the patients having distant metastasis. During the follow-up period, 3221 (83.7%) patients died and, of all the deceased patients, 2935 (88.4%) died of lung cancer while only 286 (11.6%) died from other diseases or causes. The occurrence of distant metastasis was closely related to the patient’s age, primary tumour site, tumour grade, T stage, N stage, surgery of primary site, radiation therapy, and chemotherapy (p<0.05). Compared to patients without metastasis, whose median OS was 13 months, the median OS of patients with metastasis was 6 months (lung), 5 months (liver), 5 months (bone), 4 months (brain), and 3 months (multiple organs). Conclusions: distant metastasis indicates a poor prognosis in NSCLC patients. There were significant differences in the prognosis of different metastatic sites and the order of their OS from high to low was: no metastasis > lung metastasis, liver metastasis, bone metastasis > brain metastasis, multiple organ metastasis.

Objective: To explore the characteristics and prognostic factors of distant metastatic gastric adenocarcinoma (DMGA). Methods: The data of DMGA patients who were enrolled in the SEER database from 2010 to 2017 was obtained. The Chi-squared test was performed for comparison between groups. The Kaplan-Meier method and the log-rank test was used for survival analysis. Univariate and multivariate Cox regression analysis was used to identify independent prognostic factors. Results: A total of 2324 DMGA patients was identified. The association between different metastatic sites and clinicopathological characteristics was detected. The survival curves of patients with single and double-organ metastasis were established. The multivariate Cox analysis indicated that age, histological grade, T stage, N stage, surgery and tumor size were independent prognostic factors. Conclusion: DMGA patients have poor outcomes, especially brain metastasis, bone metastasis, liver-brain metastasis, and lung-brain metastasis. Age <60 years old and cancer-directed surgery indicated a better prognosis, while higher T and N stage, higher grade and tumor size ≥5 cm indicated a worse prognosis.